BioSig Announces New Advisory Board Member Lorraine Spurge
March 24, 2023 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, March 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
BioSig Confirms No Exposure to Silicon Valley Bank
March 13, 2023 07:30 ET
|
BioSig Technologies, Inc.
Westport, CT, March 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
BioSig Regains Compliance With All Nasdaq Listing Standards
February 22, 2023 07:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering...
BioSig Appoints Former Qorvo CFO as Successor to Steve Chaussy
February 07, 2023 08:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly brings 15 years of public company...
BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments
January 19, 2023 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Jan. 19, 2023 (GLOBE NEWSWIRE) -- To date, the Company's FDA 510(k)-cleared PURE EP™ System has been used in approximately 3,000 patient cases across the United States The...
BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology
January 10, 2023 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Leading Midwest healthcare system reports significant cost savings and noise reduction following evaluation of the PURE EP™ System Medical center...
Update: BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
December 14, 2022 16:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- - BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
BioSig’s PURE EP™ System Demonstrates Potential Time and Cost Savings at the 15th APHRS Scientific Session in Singapore
December 14, 2022 08:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering...
BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology
December 06, 2022 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
November 07, 2022 07:00 ET
|
InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...